Back to mobile site

Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)

March 1, 2022 9:21 AM EST Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $90.00 price target on Axsome Therapeutics (NASDAQ: AXSM), following the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login